Lodoco — CareFirst (Caremark)

Initial criteria

• Patient age ≥ 18 years
• Lodoco is being prescribed to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death
• Patient meets ONE of the following: established atherosclerotic disease (includes acute coronary syndromes, history of MI, angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial disease (PAD)) OR multiple risk factors for cardiovascular disease (e.g., family history of premature atherosclerotic cardiovascular disease, primary hypercholesterolemia, metabolic syndrome, chronic kidney disease)
• Patient is currently receiving guideline-directed management and therapy (GDMT) for chronic coronary disease (e.g., antiplatelet or anticoagulant, lipid-lowering agent, beta-blocker, renin-angiotensin inhibitor, etc.)

Approval duration

12 months